高嘉宏
教授

 
個人學經歷
 
《學歷》
台灣大學 醫學系學士(1980-1987)
台灣大學 臨床醫學研究所博士(1991.9-1994.12)

《經歷》
1.臺灣肝臟研究學會 秘書長 (2004-2005)
2.台灣消化系醫學會 副秘書長(2003-2006)
3.國立台灣大學醫學院附設醫院肝炎研究中心主任 (2003-2009)

《現職》
1.國立台灣大學醫學院附設醫院內科部主治醫師 (1992-迄今)
2.國立台灣大學醫學院臨床醫學研究所終身職特聘教授 (2006-迄今)
3.國立台灣大學醫學院臨床醫學研究所教授 (2003-迄今)
4.教育部國家講座教授
5.美國肝病學會(AASLD)院士
 
研究專長
 
 
    病毒性肝炎、分子病毒學、肝臟學、胃腸學

    研究室可提供學習之實驗技術與設備
    1.研究室可提供學習之實驗技術:
    PCR, Squencing, SSCP, Phylogenetic analysis, RT-PCR, .
    Real time PCR, PCR-RFLP.

    2.研究室設備:
    PCR machine, SSCP machine.
 
五年內著作
 
 五、著作目錄(2008.1.1迄今):
1. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS. Pegylated Interferon Alfa-2a versus Standard Interferon Alfa-2a for Treatment-Naive Dialysis Patients with Chronic Hepatitis C: A Randomized Study. Gut 2008;57:525-530 (Correspondence author).
2. Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008;23:779-82 (Correspondence author).
3. Liu CH, Hsu SJ, Liang CC, Tsai FC, Lin JW, Liu CJ, Yang PM, Lai MY, Chen PJ, Chen JH, Kao JH, Chen DS. Esophageal varices: noninvasive diagnosis with duplex Doppler US in patients with compensated cirrhosis. Radiology 2008;248:132-9 (Correspondence author).
4. Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, Lai MY, Chen PJ, Kao JH, Chen DS. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver International 2008;28:271-7 (Correspondence author).
5. Kao JH, Chen DS. Critical analysis of the immune tolerance phase of chronic HBV infection: natural history and diagnosis. Current Hepatitis Report 2008.
6. Hsu CS, Kao JH. Insulin resistance, adipocytokines and HCV infection: a missing link? Hepatology 2008;47:760-1 (Correspondence author).
7. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-45 (Correspondence author).
8. Kao JH, Chen DS. HBV genotypes: epidemiology and implications regarding natural history: An update. Current Hepatitis B Report 2008.
9. Lin CL, Kao JH. Combination of hepatitis B viral factors and advanced liver disease in HBeAg-negative patients: the more, the worse? Gastroenterology 2008;134:1270-1 (Correspondence author).
10. Tseng TC, Kao JH. HBV genotype and clinical outcome of chronic hepatitis B: facts and puzzles. Gastroenterology 2008;134:1272-3 (Correspondence author).
11. Liu CJ, Kao JH. Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: the story beyond A1762T/G1764A mutations. J Gastroenterol Hepatol 2008;23:347-50 (Correspondence author).
12. Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Metabolic Profiles in Patients with Chronic Hepatitis C: A Case-Control Study. Hepatology International 2008;2: 250-257 (Correspondence author).
13. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, Chen DS. Higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 2008;28:1034-1041 (Correspondence author).
14. Huang YW, Lin CL, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B viral genotype in Taiwanese patients with acute hepatitis B. Hepato-Gastroenterology2008;55:633-5 (Correspondence author).
15. Kao JH. Diagnosis of Hepatitis B virus infection through serological and virological markers. Expert Review of Gastroenterology and Hepatology 2008;2:553-62 (Correspondence author).
16. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antiviral Therapy 2008;13:613-24 (Correspondence author).
17. Su TH, Liu CJ, Chen PJ, Chen DS, Kao JH. Acute fatty liver of pregnancy with concurrent acute hepatitis B virus Infection. Am J Gastroenterol 2008;103:2663-5 (Correspondence author).
18. Tseng PH, Liu CJ, Kao JH, Shun CT, Chen PJ, Chen DS. Disease progression in a patient with nonalcoholic steatohepatitis. J Formos Med Assoc 2008;107:816-21.
19. Liu CH, Liu CJ Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Peginterferon alfa-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260–9 (Correspondence author).
20. Kao JH, Chen DS. Universal hepatitis B vaccination: killing two birds with one stone. Am J Med 2008;121:1029-1031.
21. Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol 2009 Mar;104:598-604. (Correspondence author).
22. Liu CJ, Jeng YM, Chen CL, Cheng HR, Chen PJ, Chen TC, Liu CH, Lai MY, Chen DS, Kao JH. Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in chronic hepatitis B patients. J Infect Dis 2009;199:742-749 (Correspondence author).
23. Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY, Liu CJ, Chen PJ, Hwang LH. The nonstructural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol 2008;49:899-907.
24. Liu CH, Liang CC, Liu CJ, Tsai HB, Hung PH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH. Pegylated interferon alfa-2a plus low dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 2009;58:314-6. (Correspondence author).
25. Chuang JY, Yang SS, Lu TY, Hsieh YY, Chen CY, Chang SC, Chang CS, Yeh HZ, Kao JH. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009;41:424–430 (Correspondence author).
26. Tseng TC, Liu CJ, Hsieh SC, Chen PJ, Lai MY, Chen DS, Kao JH. Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. Dig Liver Dis 2009;41:322–323 (Correspondence author).
27. Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antiviral Therapy 2009;14:45-54. (Correspondence author).
28. Liu CJ, Chuang, WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Ting SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic hepatitis C and B infections. Gastroenterology 2009;136:496-504.
29. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH. Association of hepatitis B viral factors with response to lamivudine therapy in chronic hepatitis B patients with serum ALT over 5 times upper limit of normal. Antiviral Therapy 2009;14:203-10 (Correspondence author).
30. Huang YW, Hu CY, Chen CL, Liao YT, Liu CJ, Lai MY, Chen PJ, Yang SS, Hu JT, Chen DS, Kao JH. Human Leukocyte Antigen-DRB1*1101 Correlates with Less Severe Hepatitis Activity in Taiwanese Male Hepatitis B Carriers. J Med Virol 2009;81:588-93. (Correspondence author).
31. Lin CL, Kao JH. HBV genotypes and chronicification of acute hepatitis B: more questions than answers. Gut (in press) (Correspondence author).
32. Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, Wang LY, Kao JH. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009;24:1411-6. (Correspondence author).
33. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24:346-53.
34. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol. 2009;24:1352-7.
35. Hsu CS, Kao JH. Esomeprazole for asthma. N Engl J Med 2009;361:206 (Correspondence author).
36. Kao JH. Telaprevir for chronic HCV infection. N Engl J Med 2009 30;361:534 (Correspondence author).
37. Chang LC, Chung CS, Liu CJ, Kao JH. Metabolic syndrome on top of chronic hepatitis B: The more, the worse? Gut 2010;59:276-7 (Correspondence author).
38. Chu CH, Yang AM, Kao JH, Liu CY, Chang WH, Yang WS. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism is associated with choledocholithiasis in Taiwanese patients. J Gastroenterol Hepatol 2009; 24:1559-61.
39. Hsieh TH, Tseng TC, Liu CJ, Lai MY, Chen PJ, Hsieh HL, Chen DS, Kao JH. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antiviral Therapy 2009;14:1157-63. (Correspondence author).
40. Hsu CS, Chen DS, Kao JH. Both insulin resistance and ALT level increase the risks of cardiovascular disease in fatty liver disease patients. Hepatology 2009;50:989 (Correspondence author).
41. Hsu CS, Kao JH. Capsule endoscopy versus colonoscopy. N Engl J Med. 2009 15;361:1608 (Correspondence author).
42. Hsu CS, Kao JH. Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C. N Engl J Med. 2009;361:1808-9 (Correspondence author).
43. Huang YW, Liao YT, Chen W, Chen CL, Hu JT, Liu CJ, Lai MY, Chen PJ, Chen DS, Yang SS, Kao JH. Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Gene and Immunity 2010;11:87-93 (Correspondence author).
44. Wang CC, Kao JH. Alanine aminotransferase, metabolic syndrome and cardiovascular disease: a missing link? Am J Gastroenterol 2010;105:224 (Correspondence author).
45. Wang CC, Kao JH. Carvedilol versus variceal band ligation for prevention of the first variceal bleed. Hepatology 2010;51:718-9 (Correspondence author).
46. Wang CC, Kao JH. From liver markers to life expectancy. Hepatology 2010;51:720 (Correspondence author).
47. Huang YW, Kao JH. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antiviral Therapy 2010;15:177-84 (Correspondence author).
48. Lin CL, Kao JH. Clinical implications of hepatitis B virus variants. J Formosan Med Assoc 2010;109:321-5 (Correspondence author).
49. Wang CC, Kao JH. HCV Infection, lipid and coronary heart disease: a Pandora’s box Hepatology 2010;51:343 (Correspondence author).
50. Hsu CS. Kao JH. HCV Infection and Metabolic Syndrome. J Formosan Med Assoc 2010;109:403–40 (Correspondence author).
51. Wang CC, Kao JH. Metformin improves sustained virologic response in difficult-to-cure hepatitis C: more questions than answers. Hepatology 2010;51:1082 (Correspondence author).
52. Wang CC, Kao JH. A novel antibody associated with autoimmune pancreatitis. N Engl J Med. 2010;362:759-61 (Correspondence author).
53. Huang ZS, Huang TS, Wu TH, Chen MF, Hsu CS, Kao JH. Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus --- A ten-year observation. J Gastroenterol Hepatol (in press) (Correspondence author).
54. Hsu CS, Kao JH. Outcomes of HCV treatment -- Who does well and who does not? J Gastroenterol Hepatol (in press) (Correspondence author).
55. Hsu CS, Kao JH. Use of statin and gallstone risk. JAMA 2010;303(:1146 (Correspondence author).
56. Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Noninvasive monitoring of hepatic fibrosis by aspartate aminotransferase-to-platelet ratio index in hemodialysis patients with chronic hepatitis C. Kidney International 2010;78:103-9 (Correspondence author).
57. Wang CC, Kao JH. Preoperative drainage in pancreatic cancer. N Engl J Med 2010 :362:1343 (Correspondence author).
58. Liaw YF, Lau GKK, Kao JH, Gane E. HBeAg seroconversion: A critical event in chronic hepatitis B virus infection. Digestive Disease and Sciences 2010 Mar 18. [Epub ahead of print]
59. Liu CH Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, Hung-Bin Tsai HB, Lai MY, Chen PJ, Chen DS, Kao JH. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clinical Infectious Diseases 2010;51:541-9 (Correspondence author).
60. Lin CL, Kao JH. Optimal Management of Hepatocellular Carcinoma: Challenges and Opportunities J Gastroenterol Hepatol 2010;25:1336-8 (Correspondence author).
61. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol. 2010;25:657-63.
62. Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, Lin ZY, Hu TH, Chen CH, Hung CH, Wang JH, Chen CL, Kao JH, Lai MY, Liu CH, Su TH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Chen PJ, Liu CJ, Chen DS. HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. J Infect Dis 2010;202:86-92.
63. Wang CC, Kao JH. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(:2423 (Correspondence author).
64. Lui YY, Tsoi KK, Wong VW, Kao JH, Hou JL, Teo EK, Mohamed R, Piratvisuth T, Han KH, Mihm U, Wong GL, Chan HL. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antiviral Therapy 2010;15:145-55.
65. Sung JJ, Amarapurkar D, Chan HL, Cheng J, Kao JH, Han KH, Piratvisuth T. Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed? Antivir Ther. 2010;15:607-16.
66. Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS, Kao JH, Chen DS, Liu CJ. The clinical significance of occult hepatitis B transfusion in Taiwan - a look-back study. Transfusion Medicine 2010 Aug 18. [Epub ahead of print].
67. Tong MJ, Hsu L, Hsien C, Kao JH, Durazo FA, Saab S, Blatt LM. A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int 2010;4:516-22.
68. Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: Epidemiological and molecular biological aspects. Advances in Cancer Research 2010;108:21-72.
69. Tseng PH, Wu MS, Kao JH. Recent advances in clinical application of gut hormones. J Formosan Med Assoc 2010;109:859-61 (Correspondence author).
70. Tseng TC, Liu CJ, Kao JH. Implications of hepatitis B virus genomic variations on treatment outcomes. Current Pharmacogenomics and Personalized Medicine (in press) (Correspondence author).
71. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol. 2011;26 Suppl 1:123-30 (Correspondence author).
72. Wen WH, Chen HL, Ni YH, Hsu HY, Kao JH, Chang MH. Secular trend of viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology 2011;53:429-36.
73. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol 2011;26:228-39 (Correspondence author).
74. Hsu SJ, Hsu CS, Liu CH, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. Hepatitis C Virus Core Gene Polymorphisms Correlate with Severity of Liver Fibrosis but not Sustained Virologic Response to Combination Therapy in Patients with Genotype 1 Infection. Antiviral Therapy (in press) (Correspondence author).
75. Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Serum hepatitis B surface antigen concentration correlates with HBV-DNA level in patients with chronic hepatitis B. Antiviral Therapy 2010;15:1133-9. (Correspondence author).
76. Huang YW, Yang SS, Kao JH. Pathogenesis and management of alcoholic liver cirrhosis: a review. Hepatic Medicine: Evidence and Research 2011:3 1–11 (Correspondence author).
77. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 2011;6 :1057-1065 (Correspondence author).
78. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH. Impact of host and viral factors on HBeAg-positive chronic hepatitis B patients receiving peginterferon alfa-2a therapy. Antiviral Therapy (in press) (Correspondence author).
79. Mah YH, Hsu CS, Liu CH, Liu CJ, Lai MY, Chen PJ, Chen, Kao JH. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int 2011 (in press) (Correspondence author).
80. Ochi H, Makeawa T, Abe H, Yasufumi Hayashida Y, Rikita Nakano R, Michio Imamura M, Hiraga N, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J Gen Virol 2011;92:1071-81.
81. Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Proc Natl Acad Sci U S A. 2011;108:3719-24 (Correspondence author).
82. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS. Kao JH. Serum Hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-525 (Correspondence author).
83. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation post-cancer chemotherapy: pathogenesis and management. Hep Int (in press). (Correspondence author).
84. Liang CC, Liu CH, Lin YL, Liu CJ, Chiang BL, Kao JH. Functional impairment of dendritic cells in hepatitis C virus genotype 1 patients who failed peginterferon plus ribavirin therapy. J Med Virol 2011;83:1212-20 (Correspondence author).
85. Nien HC, Cheu JC, Kao JH, Chou HC, Su CW, Chen CH. Aboriginal Taiwanese hepatitis B carriers have more favourable viral factors than Han Chinese carriers. J Med Virol 2011;83:1326-31.
86. Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, Wang JH, Lin ZY, Lu SN, Hu TH, Yu ML, Kao JH, Chuang WL, Chen PJ, Chen DS. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One. 2011;6:e20752.
87. Liu CJ, Cheng HR, Chen CL, Chen TC, Tseng TC, Wang ZL, Chen PJ, Liu CH, Chen DS, Kao JH. Effects of hepatitis B virus precore and basal core promoter mutations on expression of viral antigens: genotype B versus C. J Viral Hepatitis 2011;18:e482-e490 (Correspondence author).
88. Batoctoy KS, Tseng TC, Kao JH, Quiza FE, Garcia LH Sr, Lao-Tan J. HBV/A and HBV/C genotype predominance among patients with chronic hepatitis B virus infection in Cebu City, Philippines. Hepatol Int 2011;5:774-781.
89. Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opinion On Pharmacotherapy 2011;12:2025-40 (Correspondence author).
90. Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, Yu CJ, Lee LN, Kao JH, Yang PC. Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load. J Infection 2011;62:448-55.
91. Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Chen PJ, Chen DS, Kao JH. Serum HBV DNA level at one year post spontaneous hepatitis B e antigen seroconversion correlates with long-term outcomes. J infect Dis (in press) (Correspondence author).
92. Liu CH, Kao JH. Interleukin 28B genetic variations and response to interferon-based therapy: Asian perspectives. J Gastroenterol Hepatol 2011;26:1348-53 (Correspondence author).
93. Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther 2011 (in press) (Correspondence author).
94. Hsu CS, Kao JH. Hepatitis C virus and lipid profiles: more questions than answers? Hepatol Int 2011 (in press) (Correspondence author).
95. Hsu CS, Kao JH. Boceprevir for chronic HCV genotype 1 infection. N Engl J Med 2011;365:176-178.
96. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P; for the Good Practice in using sAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group). Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. J Hepatol. 2011 (in press).
97. Kao JH. Molecular epidemiology of hepatitis B virus. Korean J Intern Med 2011;26:255-61 (Correspondence author).
98. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Determinants of spontaneous surface antigen loss in HBeAg-negative patients with a low viral load. Hepatology 2012;55:68-76 (Correspondence author).
99. Tsai HB, Chen PC, Liu CH, Hung PH, Chen MT, Chiang CK, Kao JH, Hung KY. Association of hepatitis C virus infection and malnutrition-inflammation complex syndrome in maintenance hemodialysis patients. Nephrol Dial Transplant 2012;27:1176-1183.
100. Chen BB, Hsu CY, Yu CW, Wei SY, Kao JH, Lee HS, Shih TT. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB- DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol 2012;22:171-80.
101. Wu LW, Kao JH. Hepatitis during antituberculosis treatment. J Formos Med Assoc 2011;110:801 (Correspondence author).
102. Wang CC, Kao JH. Uncovered issues in the overview of nonalcoholic steatohepatitis. J Formos Med Assoc 2011;110:798 (Correspondence author).
103. Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat. 2012;19:e48-57 (Correspondence author).
104. Tseng TC, Kao JH. Hepatitis B virus mutants associated with hepatitis B surface antigen loss: Chicken or egg? Hepatology 2012;55:656-7 (Correspondence author).
105. Sheng WH, Hung CC, Chang SY, Liu CJ, Chen MY, Hsieh SM, Kao JH, Chen PJ, Chang SC. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. Clin Infect Dis 2012;54:548-55 (Correspondence author).
106. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SFT, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-1149 (Correspondence author).
107. Chen SH, Wu HL, Kao JH, Hwang LH. Persistent Hepatitis B Viral Replication in a FVB/N Mouse Model: Impact of Host and Viral Factors. PLoS ONE 2012;7: e36984.
108. Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, Chen PJ, Liu CJ, Chen DS. Ding-Shinn Chen. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2012;6:591–597.
109. Lin CL, Tseng TC, Su TH, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Host genetic variants and hepatitis B virologic featuresin HBeAg-negative hepatitis B carriers with long-term biochemical remission. Hepatol Int 2012;6:598–605.
110. Liaw YF, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–561.
111. Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH. Interleukin 28B genetic polymorphisms play a minor role to identify the optimal treatment duration in hepatitis C virus genotype 1 non-rapid viral responders to peginterferon plus ribavirin. Antiviral Therapy (in press).
112. Hsu CS, Kao JH. Genomic variation-guided management in chronic hepatitis C. Expert Review of Gastroenterology and Hepatology (in press) (Correspondence author).
113. Kao JH, Liu CJ, Jow GM, Chen PJ, Chen DS, Chen BF. Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. Liver International (in press).
114. Tseng TC, Liu CJ, Su TH, Yang HC, Wang CC, Chen CL, Kuo SFT, Liu CH, Cjen PJ, Chen DS, Kao JH. Young chronic hepatitis B patients with nucleos(t)ide analogues-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 2012;206:1521-31 (Correspondence author).
115. Hsu CS, Kao JH. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. Journal of the Formosan Medical Association 2012;111:527-535 (Correspondence author).
116. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Hsu CA, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Serum hepatitis B surface antigen levels Help predict disease progression in patients with low HBV loads. Hepatology (in press) (Correspondence author).
117. Chen BB, Hsu CY, Yu CW, Wei SY, JH Kao, HS Lee, TF Shih. Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with Gd-EOB-DTPA. Investigative Radiology (in press).
118. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY, Zhang J, Kao JH, Chen DS, Chen PJ, Xia NS. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut. 2012 (in press).
119. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol (in press) (Correspondence author).
120. Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol (in press) (Correspondence author).
121. Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY, Liu CH, Chen PJ, Chen DS, Kao JH. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced HBeAg seroconversion. Hepatology (in press) (Correspondence author).
122. Huang YW, Hu JT, Hu FC, Chang CJ, Chang HY, Kao JH, Yang SS, Chen DS. Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients. Antiviral Therapy (in press).
123. Hsu CS, Kao JH. Fluvastatin helps interferon-based therapy in chronic hepatitis C: fact or fiction? J Gastroenterol Hepatol (in press) (Correspondence author).
124. Hsu CS, Hsu SJ, Liu WL, Liu CH, Chen CL, Liu CJ, Chen PJ, Chen DS, Kao JH. IL-21R gene polymorphisms and serum IL-21 levels predict virologic response to interferon-based therapy in Asian chronic hepatitis C patients. Antiviral Therapy (in press) (Correspondence author).
125. Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013;8(1):e53008. doi: 10.1371/journal.pone.0053008 (Correspondence author).
126. Huang CF, Yu ML, Kao JH, Tseng TC, Yeh ML, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo AH, Chuang WL, Liu CH. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. J Clin Virol (in press).
127. Yu ML, Liu CH, Huang CF, Tseng TC, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Kao JH. Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. PLoS ONE 2012;7(12): e52048. doi:10.1371/journal.pone.0052048.
128. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ; Taiwan Liver-Net Consortium. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology 2013 (in press).
 
BACK